Thank you, Operator. Good morning, everyone. I'm joined today by Marty Stammer, our Chief Financial Officer. I stated on our last call that we are deep in execution mode at Stereotaxis. That remains the case. We have seen some of that execution during the second quarter, and I'm pleased with our progress. In the second quarter, we were excited to announce 2 important strategic agreements. In June, we announced an extension to our development alliance and supply agreement will Johnson & Johnson's Biosense Webster. Biosense Webster is the undisputed leader in the cardiac ablation market, and our long-term collaboration with Biosense has been key to Stereotaxis' development. The extension agreement ensures the continued global availability through the end of 2022 of the family of magnetic ablation catheters currently manufactured and commercialized by Biosense. The agreement also extends, without modification, the financial arrangement under which Stereotaxis receives a royalty on the sale of those catheters and the current nonexclusive nature of the collaboration. The Stereotaxis and Biosense teams work together on a daily basis to support hundreds of our joint physician customers globally. We appreciate and look forward to our continued collaboration with Biosense. In May, we announced a new collaboration with Acutus Medical, a San Diego-based private company that has developed a highly innovative cardiac mapping system. The system is unique and aligned for contactless rapid acquisition of high-resolution anatomical and electrical maps of the heart chamber. This is particularly useful for complex atrial fibrillation patients. It is expected to enable improved diagnosis of such arrhythmias and more rapid and effective procedures. Our collaboration was announced just prior to the Heart Rhythm Society's annual conference. I was pleasantly surprised by the significant positive feedback we received from physicians to this announcement, with many physicians visiting our booth, asking to be introduced to Acutus and seeking to be among the first to use the technologies together once integration is complete. Both companies are working diligently to integrate our technologies. Integration will allow for improved physician workflow and enhance Stereotaxis' automated navigation capabilities. Stereotaxis is implementing this integration using a novel open mapping application programming interface, which reflects our commitment to expanding physician choice and allowing the benefits of robotics to be paired with a broad range of innovative technologies in the electrophysiology field. This strategy is good for patients, it's good for physicians, it's good for providers and it's the path our industry should pursue. We are excited to be working with the Acutus team and look forward to introducing our integrated technologies to the market in the coming months. These two collaborations are key pieces in our strategic innovation plan. They also represent only the tip of the iceberg. Stereotaxis' commitment to internal innovation and external collaboration is strong. We are confident in our broader innovation strategy. Our strategy addresses each of the 5 core technologies utilized in a robotic cardiac ablation procedure and has the guiding goals of improving patient care, physician choice and technology availability. It provides these benefits to patients, physicians and hospitals while also improving Stereotaxis' opportunity. While execution of this plan requires investment of capital and resources in advance of any financial benefit, we believe the return on investment is attractive and that this will become evident in 2019 and beyond. I look forward to sharing additional updates as appropriate. Shifting to commercialization. We recorded another quarter of recurring revenue growth and are on track to meet our guidance of $28 million of recurring revenue for the year. This level would be the highest Stereotaxis has ever recorded in its history. While still modest, this is now the fourth quarter in a row of recurring revenue growth, which is in stark contrast to our previous history and reflects entirely what in retail would be described as same-store sales growth. Our overarching commercial strategy is to put in place the institutional infrastructure and processes to ensure that our physician customers have successful, growing robotic ablation practices. Our strategy is multipronged, and on previous calls, I described the category and various initiatives being worked on. We recently launched a patient-friendly Web page, roboticarrhythmiacare.com, as our first step in building a more informative and impactful Web presence. We also cleaned and organized our YouTube account. These follow the resurrection of our other social media accounts last year. I encourage you to visit these pages. We are working to complete several additional foundational components of commercial infrastructure. That infrastructure should enable robotic practices to effectively attract patients, capture market share in their regions and showcase the clinical and commercial benefits of adopting robotics. Successful robotic practices that do so create the environment for significant adoption of our technology. We believe our focus on building a solid commercialization infrastructure, addressing our existing customers and growing recurring revenue is appropriate at this time. We do envision a period in the coming quarters where the environment will be conducive to an effort to expand the community of robotic ablation practices and reinvigorate system sales. The market opportunity remains very significant for new robotic ablation practices. We have advanced our innovation and commercial initiatives while being financially disciplined and attentive to shareholder value. In the second quarter, we had positive free cash flow of $400,000. This increase matches what we guided for on our last quarterly call and was driven by the partial reversal of the increase in accounts receivable witnessed in the first quarter. In the first half of the year, we used $1.6 million of cash. A significant amount of this was spent on discrete innovation projects, and this amount is almost $2 million lower than the cash used in the first half of 2017. We have and continue to find ways to reduce expenses while being much more active, nimble and effective. We have a healthy organization and a good team. I expect our operating expenses to modestly increase in the second half of 2018, but I'm comfortable that with continued vigilance, we'll maintain a relatively low burn rate. Our strong balance sheet will allow us to advance our initiatives and achieve profitability without the need for additional financings. I have attempted to keep my comments brief and focused on this call. On our 2017 year-end earnings call earlier this year, I provided a broader overview on Stereotaxis, our technology, clinical value, vision and goals. I encourage you to revisit that transcript for the broader context. Before handing the call over to Marty, though, I do want to touch upon the growing body of clinical literature that supports our technology. Revisiting the clinical literature is important as the principal purpose of Stereotaxis and all innovation in our industry is ultimately to reduce the burden of disease, to reduce human suffering and to save lives. I am proud that Stereotaxis' technology consistently shows great benefits to patient care. The benefits of robotic cardiac ablation have been demonstrated in the real-world experience of over 100,000 patients treated globally and with scientific rigor in over 350 peer-reviewed publications. I want to share the results of a publication that recently came to my attention from Dr. Jin and the electrophysiology team at Ruijin Hospital in Shanghai, China. The publication assessed ablation outcomes for 152 patients suffering from a type of arrhythmia called premature ventricular contractions or PVC. 64 patients were treated utilizing robotic magnetic navigation, and 88 were treated with manual ablation catheters. No complications occurred in the patients treated robotically. In stark contrast, those treated with manual catheters had a 4.5% rate of major adverse events, primarily cardiac perforation. In addition to this reduction in adverse events, from 4.5% to 0%, patients treated robotically were exposed to 69% less radiation than those treated with a manual catheter, 3.7 minutes versus 12 minutes. Looking at efficacy, there was a trend towards increased acute procedure success, with an 88% acute success rate in the robotic arm compared to 84% in the manual arm. The breadth and strength of the clinical data supporting robotic cardiac ablation is undisputable. We are working on ways to ensure the dramatic data in this and similar clinical publications is more readily available to patients, physicians and the broader community. I will now pass the call over to Marty to discuss our financial results in more detail.
